MedTrace Logo

Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19

NCT04646031 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2023-08-08

No results posted yet for this study

Summary

This expanded access use program will provide a botanical drug of T89 for treatment use in an intermediate-size population infected with SARS-CoV-2 who have severe COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening condition.

Conditions

  • Covid19

Interventions

DRUG

T89 capsule

T89 capsule, an medicinal product for oral use under active INDs in the US is a botanical drug containing 75mg active substance of the water extract of Danshen and Sanqi.

Sponsors & Collaborators

  • Tasly Pharmaceutical Group Co., Ltd

    collaborator INDUSTRY

  • Tasly Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Patrick Meehan, PhD, MD · MultiCare Health System

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04646031 on ClinicalTrials.gov